ReGEN Biomedical focusses on growing large amounts of robust and reproducible small pieces of tissue (micro tissues) for toxicity- & pharma-screening. Functional micro-tissues present the next step in mimicking patient organs and represent the future of personalized medicine.
We are building expertise on how to assemble the micro-tissues into functional pieces of human organs, so-called macro-tissues. The micro tissues also serve as building blocks for RM-therapies and will be assembled into functional macro tissues.
It is the aim to fully automate all production platforms and equip these with advanced appropriate offline and inline quality control systems. The platform technology also enables this initiative to realize sales and licensing for specific drug screening opportunities and ex vivo disease models. The large-scale production is one of the foundations of the development of a new (manufacturing) industry around affordable Regenerative Medicine solutions.
Company Details
- Employees
- 15
- Founded
- 2021
- Address
- Manager | Regen Biomedical B.v.
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.regenbiomedical.com/
- Keywords
- Regenerative Medicine.
Regen Biomedical Questions
Regen Biomedical's website is https://www.regenbiomedical.com/
Regen Biomedical's LinkedIn profile is https://www.linkedin.com/company/regen-biomedical
Regen Biomedical has
15 employees.
View email and phone details for 15
employees at Regen Biomedical.
Regen Biomedical's industry is
Biotechnology Research
Regen Biomedical's top competitors are
Regmed Xb,
Dovideq Medical Systems Bv,
Scinus Cell Expansion B.v.,
Baat Medical,
Inreda Diabetic,
Vivolta,
Merln Institute For Technology-Inspired Regenerative Medicine,
Smart Biomaterials Consortium (Sbmc),
Neoliver,
Innovation Center For Advanced Therapies (Icat).
Regen Biomedical's categories are Biotechnology Research
Regen Biomedical's founding year is 2021
